Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?

ABSTRACT:

Background

Immune checkpoint inhibition (ICI) has significantly improved the survival of metastatic melanoma (MM) with a significant proportion of patients obtaining long-lasting responses. However, ICI also exposes patients to new, heavy, and sometimes irreversible toxicities. Thus, identifying the minimal amount of treatment time is extremely urgent.

Methods

We researched English peer-reviewed literature from electronic databases (MEDLINE and PubMed) until July 2022 with the aim of evaluating the clinical outcomes after the cessation of ICI therapy due to elective study plans, clinician-patient sharing, and adverse events.

Results

Although most of the data are from retrospective studies, considering that most patients with major responses maintain it after treatment

SUBMITTER: De Risi I 

PROVIDER: S-EPMC9599026 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature